<DOC>
	<DOCNO>NCT02805010</DOCNO>
	<brief_summary>The objective study ass single dose PK , safety , tolerability immunogenicity abatacept 125mg administered SC Chinese healthy subject .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Study Single Dose Abatacept 125mg Administered Subcutaneously</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Subjects willing participate study sign informed consent ; Healthy subject , determine clinically significant deviation normal medical history , physical examination , Electrocardiograph（ECG） , clinical laboratory determination ; Body weight male must be≥50 kg , female be≥45 kg , subject must ≤100kg ; Body mass index ( BMI ) 1926 kg/m2 ( boundary value include ) , [ BMI = body weight ( kg ) / height ( ) 2 ] ; Men woman , 1845 year old ( boundary value include ) ; Women child bear potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study , 4 week 10 week administration abatacept , male subject childbearing potential must use adequate method contraception throughout study 10 week administration investigational product manner risk pregnancy minimize ; WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal . Postmenopausal define : Amenorrhea ≥ 12 consecutive month without another cause , woman irregular menstrual period hormone replacement therapy ( HRT ) , document serum follicle stimulate hormone ( FSH ) level &gt; 35 mIU/mL ; Women use oral , implanted injectable contraceptive hormone mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy practice abstinence partner sterile ( e.g. , vasectomy ) , consider child bear potential ; WOCBP must negative serum pregnancy test within 24 hour prior study medication administration . WOCBP males subject childbearing potential unwilling unable use acceptable method avoid pregnancy 10 week administration study medication ; Women pregnant breastfeeding ; History concurrent diseases central nervous system , cardiovascular system , renal , hepatic , digestive tract , respiratory system , metabolism musculoskeletal system . ( include limit arrhythmia , bradycardia , hypotension , coronary heart disease , bronchial asthma , diabetes , hyperthyroidism , Parkinson 's disease , epilepsy , shake palsy , cancer , etc. ) . Or diseases physiological abnormality , might affect study result ; Any major surgery within 4 week enrollment ; Splenectomized subject ; Exposed investigational medication within 3 month enrollment , plan receive investigational medication study ; Donation blood plasma within 3 month enrollment , plan donate blood plasma study within one month end study ; Blood transfusion within 4 week prior enrollment ; Subjects current smoker ( defined individual smoke 6 month , smoke ≥ 5 cigarette per day screen ) , ≥ 3 cup coffee coffee drink ≥ 5 cup tea per day ; Subjects history drug alcohol abuse ; Subjects tuberculosis ( TB ) risk , specially : Having clinical , image lab test evidence current active latent pulmonary tuberculosis ; Having active pulmonary tuberculosis past 3 year , even treat ; Having history active pulmonary tuberculosis 3 year ago , unless appropriate duration type antituberculosis drug well document . Subjects herpes zoster resolve less 2 month prior enrollment ; Subjects acute chronic bacterial infection previous 3 month prior enrollment ; Subjects acute latent bacterial viral infection ( assessed investigator ) time enrollment , include subject evidence Human Immunodeficiency Virus ( HIV ) infection ; Subjects mental physical disability ; Subjects surgical medical condition , might harmful subject participate study , might change absorption , distribution , metabolism excretion investigational medication ; Heart beat rate &lt; 50 beat /min &gt; 100 beat /min ( heart rate measure brief period rest , least 5 minute . ) , systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mmHg , body temperature ( forehead ) &gt; 37.6℃ ; Hgb &lt; LLN ( low limit normal ) , absolute neutrophil count ( ANC ) &lt; 1.5×10^9/L , platelet &lt; 100×10^9/L ; bilirubin &gt; ULN ( upper limit normal ) , serum creatinine &gt; ULN ; glutamic oxaloacetic transaminase ( AST ) &gt; ULN , glutamic pyruvic transaminase ( ALT ) &gt; ULN ; Subject active infection , positive hepatitisB surface antigen ( HBsAg ) , hepatitisC antibody ( HCVAb ) , HIVAb ; Positive urinalysis protein , abnormal urinalysis test judge clinical significance investigator ; History drug allergy , postural hypotension , idiopathic allergy ; Prior exposure abatacept ( CTLA4Ig ) , belatacept ( LEA29Y ) leukocyte deplete agent ; Use prescription drug within 4 week ( 5 halflives , whichever long ) prior enrollment , Use OTC medication herbal preparation within 1 week prior enrollment , unless medical monitoring show drug clear ; Vaccination live vaccine within 4 week prior study medication administration Day 1 ; Administration oral polio vaccine subject house hold contact course study ; Prisoners subject involuntarily incarcerate ; Subjects compulsorily detain treatment either psychiatric physical ( e.g. , infectious disease ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>